Overview

Veterinary Biologics Market is predicted to value over USD xx billion by 2027 end with a CAGR of over xx% during the forecast period 2020 to 2027.

Biologics drugs are used for boosting the immune system to defend the body against infections. Veterinary biologics products are derived from biological processes and living organisms. They are used for preventing, treating or diagnosing animal function and diseases using an immunological procedure. Rising occurrence of chronic animal diseases, increased emphasis of key players in R&D of novel veterinary biological products in combating newly emerged animal diseases are predicted to boost the veterinary biologics market growth. Furthermore, growing investments made by government organizations and increased insistence for meat, milk, fish and eggs are some other factors responsible for the proliferation of the market. Moreover, technological advancement in veterinary biologics like immunomodulators and monoclonal antibodies shall boost the market growth. For instance, Zoetis’s Cytopoint, which is the first of its kind monoclonal antibody for veterinary use by EU.

Market Segmentation:

By Product
•    Diagnostic Kits
•    Vaccines
•    Antiserums and Antibodies
•    Immunomodulators
•    Others     
By Animal Type 
•    Companion Animals
•    Livestock Animals    
By Disease Type
•    Foot & Mouth Disease
•    Tuberculosis and Brucellosis
•    Bluetongue
•    Others
By Distribution Channel
•    Veterinary Clinics
•    Veterinary Hospitals 
•    Others
By Region
•    North America
•    Europe
•    Asia-Pacific
•    Latin America
•    Middle East and Africa

The market is categorised into product, animal type, disease type, distribution channel and region. The product segment is diversified into diagnostic kits, vaccines, antiserums and antibodies, immunomodulators and others. The vaccines segment is predicted to hold the largest veterinary biologics market share owing to technological advancements in vaccine development along with consistent resistance of drugs by pathogens. Furthermore, the development of veterinary vaccines has preclinical trial requirements and non-stringent regulations. Thus, emerging market players have the opportunity of entering the market with advanced product developments. The animal type segment is classified into companion animals and livestock animals. Veterinary biologics are mainly used on livestock animals which is the reason this segment is predicted to lead the market during the forecast period. The disease type segment is fragmented into foot & mouth disease, tuberculosis and brucellosis, bluetongue and others. The distribution channel segment is diversified into veterinary clinics, veterinary hospitals and others. The veterinary hospitals segment is predicted to lead the market owing to bolstering governmental support along with the provision of all veterinary treatments.

Regional Analysis:

The North America region subjugated the market due to rising issues regarding pet healthcare and high product costs. Favourable support from the government for developing novel biologic drugs is predicted to boost the market in the European region. The Biotechnology and Biological Sciences Research Council, in December 2015, funded over 5 million GBP for developing poultry vaccines to the London School of Tropical Medicine and Hygiene. Mandates in government necessities for animal immunization, increasing demand for zoonotic and rising ownership of companion animals are some of the veterinary biologics market trends in the Asia Pacific region.

Competitive Landscape:                            

Some of the key market players associated are Zoetis Inc., Merck Animal Health, Boehringer Ingelheim GmbH, Bayer AG, Eli Lilly & Company, Abaxis, OMEGA, Hebei Veyong Animal Pharmaceutical Co. Ltd.

FutureWise Key Takeaways:

•    Growth prospects
•    SWOT analysis 
•    Key market trends 
•    Key data-points affecting market growth

Objectives of the Study:

•    To provide with an exhaustive analysis on the global veterinary biologics market by product, by animal type, by disease type, by distribution channel and by region
•    To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
•    To evaluate and forecast micro-markets and the overall market 
•    To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa
•    To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:

•    We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
•    The customization Mobility Care offered are free of charge with purchase of any license of the report
•    You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
          1.1 Objectives of the Study 
          1.2 Market Definition 
          1.3 Market Scope 
                1.3.1 Years Considered for the Study
                1.3.2 Market Covered
          1.4 Currency
          1.5 Limitations 
          1.6 Stakeholders     
2. Research Methodology 
          2.1 Research Data 
                2.1.1 Secondary Data
                         2.1.1.1 Key Data from Secondary Sources
                2.1.2 Primary Data
                         2.1.2.1 Key Data from Primary Sources
          2.2 Market Size Estimation 
          2.3 Market Breakdown and Data Triangulation 
          2.4 Assumptions for the Study  
3. Executive Summary
          3.1 Market Outlook
          3.2 Segment Outlook
          3.3 Competitive Insights
4. Market Variables, Trends & Scope
          4.1 Market Lineage Outlook
          4.2 Penetration and Growth Prospect Mapping
          4.3 Industry Value Chain Analysis
          4.4 Cost Analysis Breakdown
          4.5 Technology Overview
          4.6 Regulatory Framework on Country Level
               4.6.1 Reimbursement Framework    
               4.6.2 Standards and Compliances
5. Market Overview
          5.1 Market Dynamics
                5.1.1 Market Driver Analysis         
                5.1.2 Market Restraint Analysis         
                5.1.3 Industry Challenges                  
6. Market Analysis tools                    
          6.1 Industry Analysis - Porter’s
                6.1.1 Supplier Power
                6.1.2 Buyer Power
                6.1.3 Substitution Threat
                6.1.4 Threat from new entrants
                6.1.5 Competitive Rivalry                 
          6.2 Pestel Analysis
                6.2.1 Political Landscape
                6.2.2 Environmental Landscape
                6.2.3 Social landscape
                6.2.4 Technology landscape
                6.2.5 Legal Landscape
7. Veterinary Biologics Market, By Product Historical Analysis 2015 to 2019 and Forecast 2020-2027 (USD million)
          7.1 Diagnostic Kits
          7.2 Vaccines
          7.3 Antiserums and Antibodies
          7.4 Immunomodulators
          7.5 Others                         
8. Veterinary Biologics Market, By Animal Type Historical Analysis 2015 to 2019 and Forecast 2020-2027 (USD million)
          8.1 Companion Animals
          8.2 Livestock Animals    
9. Veterinary Biologics Market, By Disease Type Channel Historical Analysis 2015 to 2019 and Forecast 2020-2027 (USD million)
          9.1 Foot & Mouth Disease
          9.2 Tuberculosis and Brucellosis
          9.3 Bluetongue
          9.4 Others
10. Veterinary Biologics Market, By Distribution Channel Historical Analysis 2015 to 2019 and Forecast 2020-2027 (USD million)
          10.1 Veterinary Clinics
          10.2 Veterinary Hospitals 
          10.3 Others
11. North America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
          11.1. Introduction
          11.2. Historical Market Size (USD Mn) Analysis By Country, 2015-2019
                11.2.1. U.S.
                11.2.2. Canada
                11.2.3. Mexico 
                11.2.4. Rest of North America
          11.3 Market Size (USD Mn) Forecast for North America 2020-2027
12. Latin America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
          12.1. Introduction
          12.2. Regional Market Trends
          12.3. Historical Market Size (US$ Mn) Analysis By Country, 2015-2019
                12.3.1. Brazil
                12.3.2. Venezuela
                12.3.3. Argentina
                12.3.4. Rest of Latin America
          12.4 Market Size (US$ Mn) Forecast for Latin America 2020-2027
13. Europe Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
          13.1. Introduction
          13.2. Historical Market Size (US$ Mn) Analysis By Country, 2015-2019
               13.2.1. Germany
                13.2.2. U.K
                13.2.3. France
                13.2.4. Italy
                13.2.5 Switzerland
                13.2.6. Spain
                13.2.7. Russia
                13.2.8. Poland
                13.2.9. Rest of Western Europe
          13.3 Market Size (US$ Mn) Forecast for Europe 2020-2027
14. Asia Pacific Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
          14.1 Introduction
          14.2 Historical Market Size (USD Mn) Analysis By Country, 2015-2019
                 14.2.1 Japan
                 14.2.2 China
                 14.2.3 Singapore
                 14.2.4 Korea         
                 14.2.5 India
                 14.2.6 Australia and New Zealand
                 14.2.7 ASEAN
                 14.2.8 Rest of Asia Pacific
          14.3 Market Size (US$ Mn) Forecast for Asia Pacific 2020-2027
15. Middle East and Africa Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
    15.1 Introduction
    15.2 Historical Market Size (USD Mn) Analysis By Country, 2015-2019
        15.2.1 UAE
        15.2.2 South Africa
        15.2.3 Egypt
        15.2.4 Saudi Arabia
        15.2.5 Rest of MEA
    15.3 Market Size (US$ Mn) Forecast for MEA 2020-2027
16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Type and Technology Portfolio, Financial Layouts)
    16.1 Zoetis Inc.
            16.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.1.2. Product Portfolio
            16.1.3. SWOT Analysis
            16.1.4. Financial Overview
            16.1.5. Strategic Overview
    16.2 Merck Animal Health
              16.2.1. Company Overview (HQ, Business Segments, Employee Strength)
              16.2.2. Product Portfolio
              16.2.3. SWOT Analysis
              16.2.4. Financial Overview
              16.2.5. Strategic Overview
    16.3 Boehringer Ingelheim GmbH
              16.3.1. Company Overview (HQ, Business Segments, Employee Strength)
              16.3.2. Product Portfolio
              16.3.3. SWOT Analysis
              16.3.4. Financial Overview
              16.3.5. Strategic Overview
    16.4 Bayer AG
             16.4.1. Company Overview (HQ, Business Segments, Employee Strength)
             16.4.2. Product Portfolio
             16.4.3. SWOT Analysis
             16.4.4. Financial Overview
             16.4.5. Strategic Overview
    16.5 Eli Lilly & Company
              16.5.1. Company Overview (HQ, Business Segments, Employee Strength)
              16.5.2. Product Portfolio
              16.5.3. SWOT Analysis
              16.5.4. Financial Overview
              16.5.5. Strategic Overview
    16.6 Abaxis
              16.6.1. Company Overview (HQ, Business Segments, Employee Strength)
              16.6.2. Product Portfolio
              16.6.3. SWOT Analysis
              16.6.4. Financial Overview
              16.6.5. Strategic Overview
    16.7 OMEGA
             16.7.1. Company Overview (HQ, Business Segments, Employee Strength)
             16.7.2. Product Portfolio
             16.7.3. SWOT Analysis
             16.7.4. Financial Overview
             16.7.5. Strategic Overview
    16.8 Hebei Veyong Animal Pharmaceutical Co. Ltd.
              16.8.1. Company Overview (HQ, Business Segments, Employee Strength)
              16.8.2. Product Portfolio
              16.8.3. SWOT Analysis
              16.8.4. Financial Overview
              16.8.5. Strategic Overview    
17. Impact of COVID-19
    17.1. Positive influence on the healthcare industry
    17.2. The financial disruption of the manufacturing sector
    17.3. Impact of COVID-19 on emerging companies
    17.4. Significant mandates in the healthcare regulations initiated by administrations
    17.5. The overall economic slowdown of the developing and developed nations
18. Competitive Intelligence and Competitive Matrix
    18.1 Competitive Intelligence
    18.2 Competitive Matrix
19. Major Deals and Strategic Alliances Analysis
    19.1 Joint ventures
    19.2 Mergers and acquisitions              
    19.3 Licensing and partnerships
    19.4 Technology Collaborations
    19.5 Strategic Divestments
    19.6 Market Entry Strategies                        
20. Relevant Case Studies and Latest News Updates
21. Key Market Takeaway Points from the Market Analysts at Future Market Analytics 

Tables

Figures